BMS’s Opdivo On Track For Esophageal Cancer Indication

 
• By Sten Stovall

Opdivo showed a 23% fall in the risk of death and 2.5-month improvement in median overall survival compared to chemotherapy in Phase III esophageal cancer trial.

Esophageal cancer
Opdivo Extended Overall Survival In ATTRACTION-3 Trial Versus Chemo • Source: Shutterstock

More from Immuno-oncology

More from Anticancer